Abstract
Cirrhotic cardiomyopathy is a recently identified pathological condition defined as “a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease”. Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussion of data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.
Keywords: Cirrhotic cardiomyopathy, hyperdynamic circulation, diastolic dysfunction, portal hypertension, peripheral vasodilation, drug targets
Cardiovascular & Hematological Disorders-Drug Targets
Title: Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Volume: 7 Issue: 1
Author(s): Massimo Pozzi, Laura Ratti, Cristina Guidi, Maria Milanese and Giuseppe Mancia
Affiliation:
Keywords: Cirrhotic cardiomyopathy, hyperdynamic circulation, diastolic dysfunction, portal hypertension, peripheral vasodilation, drug targets
Abstract: Cirrhotic cardiomyopathy is a recently identified pathological condition defined as “a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease”. Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussion of data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.
Export Options
About this article
Cite this article as:
Pozzi Massimo, Ratti Laura, Guidi Cristina, Milanese Maria and Mancia Giuseppe, Potential Therapeutic Targets in Cirrhotic Cardiomyopathy, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059074
DOI https://dx.doi.org/10.2174/187152907780059074 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Induced Pluripotent Stem Cell Technology: A Paradigm Shift in Medical Science for Drug Screening and Disease Modeling
Current Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Assessing Coronary Blood Flow Physiology in the Cardiac Catheterisation Laboratory
Current Cardiology Reviews Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design